A multicenter, randomized, controlled study of Shugan Xiaozhi Granules in the treatment of nonalcoholic fatty liver disease patients with abnormal ALT
- Conditions
- nonalcoholic fatty liver disease
- Registration Number
- ITMCTR2200005716
- Lead Sponsor
- Shenzhen TCM Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria for nonalcoholic fatty liver disease with abnormal ALT
2. TCM syndrome classification is: liver and gallbladder damp-heat, phlegm blocking blood stasis
3. Age 18-65 years old, no drinking history or drinking alcohol equivalent to ethanol <30 g/d for men and <20 for women
g/d;
1. It is complicated with Drug-induced liver injury, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, liver cancer
2. It is complicated with Heart, brain, kidney, lung, blood, severe diabetic complications, thyroid dysfunction, metabolic and gastrointestinal serious primary diseases, or mental patients
3. Women who are breastfeeding, pregnant or planning to become pregnant
4. Abnormal transaminases greater than 5 times the upper limit of normal, and creatinine greater than the upper limit of normal
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method liver function;fasting blood sugar;uric acid;lipid profile;Body mass index;hepatobiliary ultrasound;
- Secondary Outcome Measures
Name Time Method